Emergent BioSolutions Inc. announced it has completed the sale of its drug product facility in Baltimore-Camden to an affiliate of B...
-Parse Biosciences, a leading provider of cost-effective and scalable solutions for single-cell sequencing, today announced an agreement with the Taiwane...
Senhwa Biosciences, Inc. (TPEx: 6492), announced IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with c...
Bora Pharmaceuticals Co., Ltd. announced that it has successfully entered into an agreement for Emergent BioSolutions’ sterile man...
Incyte and China Medical System Holdings Limited are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology m...
Bora Pharmaceuticals Co., Ltd. announced that it has completed the acquisition of Upsher-Smith Laboratories, LLC. (“Upsher-Smith”),...
The highly anticipated BIO Asia–Taiwan 2024 has officially opened its registration for attendees. Scheduled to take place from July 24 to 28 ...
Travere Therapeutics, Inc. announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endot...
Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a diversified portfolio of 48 generic products with manufacturing facilities in Plymouth a...
The trial is a phase II multi-center, randomized-controlled interventional prospective study, and the purpose of this trial is to investigate whether early...
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization ...
Additionally, Dr. Steve Hsu, Chairman of Genovior Biotech Corporation, has been appointed as the CEO of Polaris Group. This significant decision not only a...
This partnership leverages Taiwan Bio’s world-class expertise in cellular therapy manufacturing and TRACT Therapeutics’ innovative immune modul...
The Healthcare+ Expo Taiwan, currently taking place at Nangang Exhibition Hall 1 from November 30 to December 3, 2023, is poised to redefine the landscape ...
© 2024 Biopharma Boardroom. All Rights Reserved.